Escient Pharmaceutials Closes $40m in Series A Funding

Escient Pharmaceutials, a San Diego, CA-based biotech company, closed $40m in Series A funding.

Backers included The Column Group, 5AM Ventures and Osage University Partners. In conjunction with the funding, JJ Kang, Ph.D., Principal at The Column Group, Andrew J. Schwab, Founder and Managing Partner at 5AM Ventures, and Charles S. Zuker, Ph.D., Professor of Biochemistry, Molecular Biophysics and Neuroscience at Columbia University and a Howard Hughes Medical Institute investigator, joined Escient’s board.

The company will use the funds to to build out its team, advance its pipeline, and progress its initial preclinical programs to clinical study.

Co-founded by Alain D. Baron, M.D., Chief Executive Officer (CEO), and Marcus F. Boehm, Ph.D., Chief Scientific Officer (CSO), Escient Pharmaceuticals is a biotechnology company that is advancing G Protein-Coupled Receptor (GPCR)-targeted drugs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs), to address serious, unserved medical needs across a broad range of therapeutic indications.
Escient will initially pursue therapies for neuro-immuno-inflammatory and autoreactive diseases.



Join the discussion